DNAX accessory molecule-1 (DNAM-1) is an activating receptor constitutively expressed by macrophages/dendritic cells and by T lymphocytes and Natural Killer (NK) cells, having an important role in anticancer responses; in this regard, combination therapies able to enhance the expression of DNAM-1 ligands on tumor cells are of therapeutic interest. In this study, we investigated the effect of different nitric oxide (NO) donors on the expression of the DNAM-1 ligand Poliovirus Receptor/CD155 (PVR/CD155) in multiple myeloma (MM) cells
NK cells are an important effector lymphocyte in the resolution of viral infections and the spontane...
Background: Genomic instability is a feature of multiple myeloma (MM), and impairment in DNA damagin...
Bone marrow stromal cells (BMSCs) strongly contribute to multiple myeloma (MM) progression, promotin...
A pivotal strategy to improve NK cell-mediated antitumor activity involves the upregulation of activ...
Multiple myeloma (MM) is a deadly hematologic cancer characterized by latent accumulation of clonal ...
Immunomodulatory drugs (IMiDs) have potent anti-tumor activities in multiple myeloma (MM) and are ab...
International audienceMalignant cells constitutively express Natural killer group 2, member D (NKG2D...
Copyright © 2015 Cinzia Fionda et al. This is an open access article distributed under the Creative ...
International audienceNKG2D and DNAM-1 are two activating receptors, present on the surface of NK ce...
Abstract Background Nitric oxide-releasing drugs are used for cardiovascular diseases; however, thei...
Susceptibility of dendritic cells (DCs) to tumor-induced apoptosis reduces their efficacy in cancer ...
NO• is a free radical and is involved in a number of critical physiological processes including vaso...
Angiogenesis represents a hallmark of tumor progression in Multiple Myeloma (MM), a still incurable ...
Effective cancer immunotherapy requires overcoming immunosuppressive tumor microenvironments. We\ua0...
There is much evidence to support a role for natural killer (NK) cells in controlling the progressio...
NK cells are an important effector lymphocyte in the resolution of viral infections and the spontane...
Background: Genomic instability is a feature of multiple myeloma (MM), and impairment in DNA damagin...
Bone marrow stromal cells (BMSCs) strongly contribute to multiple myeloma (MM) progression, promotin...
A pivotal strategy to improve NK cell-mediated antitumor activity involves the upregulation of activ...
Multiple myeloma (MM) is a deadly hematologic cancer characterized by latent accumulation of clonal ...
Immunomodulatory drugs (IMiDs) have potent anti-tumor activities in multiple myeloma (MM) and are ab...
International audienceMalignant cells constitutively express Natural killer group 2, member D (NKG2D...
Copyright © 2015 Cinzia Fionda et al. This is an open access article distributed under the Creative ...
International audienceNKG2D and DNAM-1 are two activating receptors, present on the surface of NK ce...
Abstract Background Nitric oxide-releasing drugs are used for cardiovascular diseases; however, thei...
Susceptibility of dendritic cells (DCs) to tumor-induced apoptosis reduces their efficacy in cancer ...
NO• is a free radical and is involved in a number of critical physiological processes including vaso...
Angiogenesis represents a hallmark of tumor progression in Multiple Myeloma (MM), a still incurable ...
Effective cancer immunotherapy requires overcoming immunosuppressive tumor microenvironments. We\ua0...
There is much evidence to support a role for natural killer (NK) cells in controlling the progressio...
NK cells are an important effector lymphocyte in the resolution of viral infections and the spontane...
Background: Genomic instability is a feature of multiple myeloma (MM), and impairment in DNA damagin...
Bone marrow stromal cells (BMSCs) strongly contribute to multiple myeloma (MM) progression, promotin...